PharmaCielo Ltd.
PCLOF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $3,480 | $1,542 | $5,309 | $1,945 |
| % Growth | 125.7% | -71% | 172.9% | – |
| Cost of Goods Sold | $2,749 | $2,911 | $4,627 | $6,253 |
| Gross Profit | $731 | -$1,369 | $681 | -$4,308 |
| % Margin | 21% | -88.8% | 12.8% | -221.5% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $5,436 | $7,895 | $10,883 | $18,073 |
| SG&A Expenses | $5,420 | $8,307 | $11,662 | $19,149 |
| Sales & Mktg Exp. | -$16 | $412 | $779 | $1,077 |
| Other Operating Expenses | $213 | $25 | $454 | $1,736 |
| Operating Expenses | $5,633 | $8,332 | $12,116 | $20,885 |
| Operating Income | -$4,902 | -$9,701 | -$11,434 | -$25,194 |
| % Margin | -140.9% | -629.2% | -215.4% | -1,295.3% |
| Other Income/Exp. Net | -$4,239 | -$6,597 | -$3,082 | -$1,436 |
| Pre-Tax Income | -$9,141 | -$16,298 | -$14,516 | -$26,630 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$9,141 | -$16,298 | -$14,516 | -$26,630 |
| % Margin | -262.7% | -1,057.1% | -273.5% | -1,369.1% |
| EPS | -0.052 | -0.1 | -0.096 | -0.18 |
| % Growth | 47.8% | -4.1% | 46.6% | – |
| EPS Diluted | -0.052 | -0.1 | -0.096 | -0.18 |
| Weighted Avg Shares Out | 175,250 | 160,081 | 150,977 | 145,638 |
| Weighted Avg Shares Out Dil | 175,250 | 160,081 | 150,977 | 145,638 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | -$57 | $2 |
| Interest Expense | $3,274 | $2,865 | $1,536 | $561 |
| Depreciation & Amortization | $1,265 | $1,414 | $1,579 | $1,319 |
| EBITDA | -$4,603 | -$12,189 | -$10,501 | -$24,840 |
| % Margin | -132.3% | -790.6% | -197.8% | -1,277.1% |